Trial Outcomes & Findings for Personalized Dietary Management in Type 2 Diabetes (NCT NCT05046886)

NCT ID: NCT05046886

Last Updated: 2026-06-18

Results Overview

MAGE will be evaluated via a continuous glucose monitor (CGM), which captures interstitial glucose readings every 15 minutes for up to 2 weeks from a sensor inserted into the participant's upper arm.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

294 participants

Primary outcome timeframe

Month 6

Results posted on

2026-06-18

Participant Flow

Participant milestones

Participant milestones
Measure
Usual Care Control (UCC)
Baseline advice about the Mediterranean-style diet and attention control.
Standardized
One-size-fits-all dietary counseling to follow a Mediterranean-style diet
Personalized
Dietary counseling to follow a Mediterranean-style diet personalized to reduce postprandial glycemic response
Overall Study
STARTED
59
61
41
Overall Study
COMPLETED
52
56
38
Overall Study
NOT COMPLETED
7
5
3

Reasons for withdrawal

Reasons for withdrawal
Measure
Usual Care Control (UCC)
Baseline advice about the Mediterranean-style diet and attention control.
Standardized
One-size-fits-all dietary counseling to follow a Mediterranean-style diet
Personalized
Dietary counseling to follow a Mediterranean-style diet personalized to reduce postprandial glycemic response
Overall Study
Lost to Follow-up
5
3
1
Overall Study
Physician Decision
1
0
0
Overall Study
Withdrawal by Subject
1
2
2

Baseline Characteristics

Personalized Dietary Management in Type 2 Diabetes

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Usual Care Control (UCC)
n=59 Participants
Baseline advice about the Mediterranean-style diet and attention control.
Standardized
n=61 Participants
One-size-fits-all dietary counseling to follow a Mediterranean-style diet
Personalized
n=41 Participants
Dietary counseling to follow a Mediterranean-style diet personalized to reduce postprandial glycemic response
Total
n=161 Participants
Total of all reporting groups
Age, Continuous
58.2 years
STANDARD_DEVIATION 13.0 • n=20 Participants
60.5 years
STANDARD_DEVIATION 12.9 • n=20 Participants
60.8 years
STANDARD_DEVIATION 10.6 • n=40 Participants
59.6 years
STANDARD_DEVIATION 12.4 • n=5 Participants
Sex: Female, Male
Female
33 Participants
n=20 Participants
43 Participants
n=20 Participants
25 Participants
n=40 Participants
101 Participants
n=5 Participants
Sex: Female, Male
Male
26 Participants
n=20 Participants
18 Participants
n=20 Participants
16 Participants
n=40 Participants
60 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
8 Participants
n=20 Participants
7 Participants
n=20 Participants
8 Participants
n=40 Participants
23 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
48 Participants
n=20 Participants
52 Participants
n=20 Participants
31 Participants
n=40 Participants
131 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
3 Participants
n=20 Participants
2 Participants
n=20 Participants
2 Participants
n=40 Participants
7 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=20 Participants
0 Participants
n=20 Participants
0 Participants
n=40 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
5 Participants
n=20 Participants
8 Participants
n=20 Participants
6 Participants
n=40 Participants
19 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=20 Participants
0 Participants
n=20 Participants
0 Participants
n=40 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
16 Participants
n=20 Participants
16 Participants
n=20 Participants
12 Participants
n=40 Participants
44 Participants
n=5 Participants
Race (NIH/OMB)
White
32 Participants
n=20 Participants
30 Participants
n=20 Participants
15 Participants
n=40 Participants
77 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=20 Participants
1 Participants
n=20 Participants
3 Participants
n=40 Participants
4 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
6 Participants
n=20 Participants
6 Participants
n=20 Participants
5 Participants
n=40 Participants
17 Participants
n=5 Participants
Region of Enrollment
United States
59 participants
n=20 Participants
61 participants
n=20 Participants
41 participants
n=40 Participants
161 participants
n=5 Participants

PRIMARY outcome

Timeframe: Month 3

Population: 1 UCC participant and 2 Personalized participants missed their 3-month assessment for MAGE and were excluded. Because of this, only 51 participants (out of a total of 52) in the UCC arm, and 36 (of 38) in the Personalized arm were analyzed.

MAGE will be evaluated via a continuous glucose monitor (CGM), which captures interstitial glucose readings every 15 minutes for up to 2 weeks from a sensor inserted into the participant's upper arm.

Outcome measures

Outcome measures
Measure
Usual Care Control (UCC)
n=51 Participants
Baseline advice about the Mediterranean-style diet and attention control.
Standardized
n=56 Participants
One-size-fits-all dietary counseling to follow a Mediterranean-style diet
Personalized
n=36 Participants
Dietary counseling to follow a Mediterranean-style diet personalized to reduce postprandial glycemic response
Mean Amplitude of Glycemic Excursion (MAGE)
75.06823474 mg/dL
Standard Deviation 23.30178744
76.58062547 mg/dL
Standard Deviation 19.4624871
75.29977814 mg/dL
Standard Deviation 23.09869692

PRIMARY outcome

Timeframe: Month 6

Population: 4 Standardized participants, 2 UCC participants, and 1 Personalized participant missed their 6-month MAGE assessment and were excluded. Because of this, only 52 participants (out of a total of 56) in the Standardized arm, 50 (of 52) in the UCC arm, and 37 (of 38) in the Personalized arm were analyzed.

MAGE will be evaluated via a continuous glucose monitor (CGM), which captures interstitial glucose readings every 15 minutes for up to 2 weeks from a sensor inserted into the participant's upper arm.

Outcome measures

Outcome measures
Measure
Usual Care Control (UCC)
n=50 Participants
Baseline advice about the Mediterranean-style diet and attention control.
Standardized
n=52 Participants
One-size-fits-all dietary counseling to follow a Mediterranean-style diet
Personalized
n=37 Participants
Dietary counseling to follow a Mediterranean-style diet personalized to reduce postprandial glycemic response
Mean Amplitude of Glycemic Excursion (MAGE)
80.60152023 mg/dL
Standard Deviation 26.53839031
75.49766632 mg/dL
Standard Deviation 21.3028359
75.91843677 mg/dL
Standard Deviation 29.42041319

SECONDARY outcome

Timeframe: Month 3

Population: 1 Standardized participant, 1 UCC participant, and 3 Personalized participants missed their 3-month assessments for HbA1c and were excluded. Because of this, only 55 (out of a total of 56) participants in the Standardized arm, 51 (of 52) in the UCC arm, and 35 (of 38) participants in the Personalized arm were analyzed.

Glycosylated hemoglobin will be evaluated from blood sampling (\~10 ml) obtained during Clinical Translational Research Center (CTRC) measurement visits, evaluated in the NYU CLIA-certified lab. . Levels from 5.7% to 6.4% indicate prediabetes, while 6.5% or higher typically indicates a diabetes diagnosis.

Outcome measures

Outcome measures
Measure
Usual Care Control (UCC)
n=51 Participants
Baseline advice about the Mediterranean-style diet and attention control.
Standardized
n=55 Participants
One-size-fits-all dietary counseling to follow a Mediterranean-style diet
Personalized
n=35 Participants
Dietary counseling to follow a Mediterranean-style diet personalized to reduce postprandial glycemic response
HbA1c Levels
6.798039216 percent
Standard Deviation 0.721800581
6.754545455 percent
Standard Deviation 0.677090229
6.9 percent
Standard Deviation 0.809865639

SECONDARY outcome

Timeframe: Month 6

Population: 3 Standardized participants, 4 UCC participants, and 2 Personalized participants missed their 6-month assessments for HbA1c and were excluded. Because of this, only 53 (out of a total of 56) participants in the Standardized arm, 48 (of 52) in the UCC arm, and 36 (of 38) participants in the Personalized arm were analyzed.

Glycosylated hemoglobin will be evaluated from blood sampling (\~10 ml) obtained during CTRC measurement visits, evaluated in the NYU CLIA-certified lab. Levels from 5.7% to 6.4% indicate prediabetes, while 6.5% or higher typically indicates a diabetes diagnosis.

Outcome measures

Outcome measures
Measure
Usual Care Control (UCC)
n=48 Participants
Baseline advice about the Mediterranean-style diet and attention control.
Standardized
n=53 Participants
One-size-fits-all dietary counseling to follow a Mediterranean-style diet
Personalized
n=36 Participants
Dietary counseling to follow a Mediterranean-style diet personalized to reduce postprandial glycemic response
HbA1c Levels
6.820833333 Percent
Standard Deviation 0.74060307
6.705660377 Percent
Standard Deviation 0.712367422
6.872222222 Percent
Standard Deviation 0.845360823

Adverse Events

Usual Care Control (UCC)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Standardized

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Personalized

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Collin J Popp, PhD, RD

NYU Langone Health

Phone: (646) 501-3427

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place